31 completed, 5 withdrawn, 4 terminated, 3 recruiting. 16 Phase 2, 15 Phase 4, 6 Phase 1, 5 Phase 3, 3 Not applicable.
Follow Acamprosate: new trials by email Literature Review of Acamprosate trials Research Report on Acamprosate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) Acamprosate calcium - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 1 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 30 | 2026-02-02 | 2026-10-01 |
| Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial IL-22, Prednisone, Acamprosate - Alcohol-associated Hepatitis | Phase 2 | Recruiting | Samer Gawrieh | 216 | 2026-01-27 | 2026-07-15 |
| Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder Acamprosate calcium, Placebo - Alcohol Use Disorder | Phase 4 | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 48 | 2025-05-07 | 2026-09-03 |
| Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations Acamprosate - Alcohol Use Disorder, Liver Transplant; Complications | Phase 2 | Completed | University of Southern California | 30 | 2021-12-01 | 2024-06-27 |
| Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence Acamprosate Calcium, Calcium Carbonate, Placebo - Alcoholism | Phase 3 | Completed | Technische Universität Dresden | 82 | 2020-08-05 | 2024-05-29 |
| Promoting Medications for Alcohol Use Disorder on the General Medicine Service audit and feedback, educational meetings, and academic detailing to promote medication receipt, Acamprosate, naltrexone, or disulfiram - Alcohol Use Disorder | Terminated | Yale University | 67 | 2020-01-01 | 2022-05-11 | |
| Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome Acamprosate, Placebo - Alcohol Use Disorder | Phase 4 | Completed | Mayo Clinic | 288 | 2019-07-15 | 2024-12-17 |
| Vortioxetine for Treatment of Depressive Mood and Alcohol Use Vortioxetine, Acamprosate - Depressive Disorder, Major, Alcoholism | Phase 2 | Unknown | Hanyang University Seoul Hospital | 128 | 2019-01-25 | 2020-08-05 |
| Acamprosate and Methazolamide for Essential Tremor Acamprosate, Placebo, Methazolamide - Essential Tremor | Phase 2 | Withdrawn | Henry Ford Health System | 2016-03-01 | 2024-09-25 | |
| Neurophysiological and Acute Pharmacological Studies in FXS Patients Acamprosate, Lovastatin, Minocycline - Fragile X Syndrome | Early Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 29 | 2016-01-01 | 2021-11-26 |
| A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome SNC-102 sustained release tablet - Tourette Syndrome | Phase 2 | Withdrawn | Synchroneuron Inc. | 2015-04-01 | 2021-04-13 | |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia SNC-102, Placebo - Drug-induced Tardive Dyskinesia | Phase 2 | Withdrawn | Synchroneuron Inc. | 2014-02-01 | 2021-04-13 | |
| Study of Acamprosate in Fragile x Syndrome acamprosate, Placebo - Fragile X Syndrome | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 46 | 2013-08-27 | 2021-02-03 |
| Study of Acamprosate in Autism Acamprosate, Placebo - Autistic Disorder | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 36 | 2013-07-02 | 2021-02-03 |
| Acamprosate in Youth With Fragile X Syndrome Acamprosate - Fragile X Syndrome, Autism Spectrum Disorders | Phase 2 | Completed | Indiana University | 14 | 2010-08-01 | 2019-07-30 |
| Alcohol Detoxification in Primary Care Treatment (ADEPT) Acamprosate - Alcoholism | Phase 4 | Completed | University of Bristol | 36 | 2009-11-01 | 2011-01-19 |
| Biomarker Study of Acamprosate in Schizophrenia Acamprosate - Schizophrenia, Schizoaffective Disorder | Phase 4 | Completed | University of Maryland, Baltimore | 36 | 2008-06-01 | 2019-09-25 |
| Acamprosate: Genes Associated With Response acamprosate - Alcoholism | Completed | Mayo Clinic | 485 | 2008-05-01 | 2013-03-22 | |
| Clinical Trial of Acamprosate for Tinnitus Acamprosate, Placebo - Tinnitus | Phase 1 | Completed | Oregon Health and Science University | 154 | 2008-01-01 | 2016-11-08 |
Showing 20 of 45. Sign in to see all of them.
Alcoholism (27) · Anxiety Disorders (3) · Depression (3) · Depressive Disorder, Major (3) · Fragile X Syndrome (3) · Schizophrenia (3) · Bipolar Disorder (2) · Mania (2) · Alcohol-Related Disorders (1) · Amyotrophic Lateral Sclerosis (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Behavior, Addictive (1) · Binge-Eating Disorder (1) · Cocaine-Related Disorders (1)
Children's Hospital Medical Center, Cincinnati (3) · Medical University of South Carolina (3) · Yale University (3) · Mayo Clinic (2) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (2) · Synchroneuron Inc. (2) · University of North Carolina, Chapel Hill (2) · Baylor College of Medicine (1) · Central Institute of Mental Health, Mannheim (1) · Finnish Institute for Health and Welfare (1) · Forest Laboratories (1) · Hannover Medical School (1) · Hanyang University Seoul Hospital (1) · Heinrich-Heine University, Duesseldorf (1) · Henry Ford Health System (1)
United States (36) · Germany (4) · Australia (1) · Finland (1) · South Korea (1) · United Kingdom (1)
Craig A Erickson, M.D. (2) · Helen Pettinati, Ph.D. (2) · Anne Lingford-Hughes (1) · Barbara J Mason, Ph.D. (1) · Barry S Fogel, MD (1) · Bernard A Fischer, M.D. (1) · Bryan K Tolliver, M.D., Ph.D. (1) · Bryan K. Tolliver, M.D., Ph.D. (1) · Craig A. Erickson, M.D. (1) · Craig Erickson, MD (1) · David Mrazek, M.D. (1) · Dennis P McNeilly, PsyD (1) · Donald W Black, MD (1) · Elizabeth Berry-Kravis, MD (1) · Florian Birkmayer, M.D. (1)
PMID 16670409, PMID 18250251, PMID 18838638, PMID 19345510, PMID 20921123, PMID 21080416, PMID 23131884, PMID 23134193, PMID 23231446, PMID 25269022, PMID 25421512, PMID 25593047, PMID 27009547, PMID 29960116, PMID 30280905, PMID 30865232, PMID 32960976, PMID 35752286, PMID 36167501, PMID 36608483, PMID 37689244, PMID 38852760, PMID 39225670
K23AA000222 (1), K24DA000435 (1), P50AA003510 (1), P50DA012756 (1), P60DA005186 (1), R01AA012602 (1), R01AA027486 (1), R03AA019571 (1), U01AA027487 (1), U10AA011715 (1), U10AA011716 (1), U10AA011721 (1), U10AA011727 (1), U10AA011756 (1), U10AA011768 (1)